Long-term administration of GPR120 agonists and pre-administration of GPR40 agonists is said to allow the possibility of development of drugs for type 2 diabetes via insulin-dependent pathway (Christiansen et al., 2008; Tikhonova et al., 2008; Oh et al., 2010). This evidence concerns the gene FFAR4 and type 2 diabetes mellitus.